

**IN THE DRAWINGS:**

In accordance with 37 C.F.R. § 1.121, Applicants hereby submit a copy of originally filed Figure 2 with proposed amendments in red for approval by the Examiner. Applicants request approval of the proposed drawing changes.

**IN THE CLAIMS:**

Please cancel claims 26-32 and 36-42 without prejudice or disclaimer to the subject matter recited therein.

Please replace claims 24 and 25 as follows:

24. (Amended) A method for the treatment of multiple sclerosis comprising administering an effective amount of naked DNA capable of expressing beta-interferon to a patient in need of such treatment.

25. (Amended) A pharmaceutical composition for the treatment of multiple sclerosis comprising an effective amount of naked DNA capable of expressing beta-interferon and a pharmaceutically acceptable carrier therefor.

**REMARKS**

Entry of the foregoing, reexamination and further and favorable reconsideration of the subject application in light of the following remarks, pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.